Hikari Power Ltd lifted its holdings in Celgene Co. (NASDAQ:CELG) by 25.4% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 71,970 shares of the biopharmaceutical company’s stock after acquiring an additional 14,570 shares during the period. Celgene makes up approximately 0.9% of Hikari Power Ltd’s investment portfolio, making the stock its 25th largest position. Hikari Power Ltd’s holdings in Celgene were worth $7,511,000 at the end of the most recent quarter.
Several other hedge funds have also added to or reduced their stakes in CELG. Capital Counsel LLC NY grew its stake in Celgene by 0.4% during the second quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock worth $214,000 after buying an additional 6 shares in the last quarter. Fort Pitt Capital Group LLC grew its stake in Celgene by 0.6% during the second quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock worth $250,000 after buying an additional 11 shares in the last quarter. Savant Capital LLC grew its stake in Celgene by 0.9% during the second quarter. Savant Capital LLC now owns 2,350 shares of the biopharmaceutical company’s stock worth $305,000 after buying an additional 20 shares in the last quarter. TCI Wealth Advisors Inc. grew its stake in Celgene by 0.9% during the second quarter. TCI Wealth Advisors Inc. now owns 3,043 shares of the biopharmaceutical company’s stock worth $395,000 after buying an additional 26 shares in the last quarter. Finally, Linscomb & Williams Inc. grew its stake in Celgene by 1.0% during the second quarter. Linscomb & Williams Inc. now owns 3,813 shares of the biopharmaceutical company’s stock worth $495,000 after buying an additional 36 shares in the last quarter. Institutional investors and hedge funds own 78.10% of the company’s stock.
A number of brokerages have issued reports on CELG. Cantor Fitzgerald set a $112.00 price objective on shares of Celgene and gave the stock a “hold” rating in a research note on Tuesday, January 23rd. UBS Group downgraded shares of Celgene from a “strong-buy” rating to a “market perform” rating and set a $160.00 price objective on the stock. in a research note on Thursday, October 26th. BMO Capital Markets reduced their price objective on shares of Celgene from $163.00 to $148.00 and set an “outperform” rating on the stock in a research note on Friday, October 27th. Robert W. Baird downgraded shares of Celgene from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $162.00 to $136.00 in a research note on Friday, October 20th. Finally, BTIG Research reiterated a “hold” rating on shares of Celgene in a research note on Sunday, October 22nd. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the stock. Celgene currently has a consensus rating of “Buy” and a consensus target price of $130.35.
Shares of Celgene Co. (NASDAQ:CELG) opened at $92.51 on Monday. The firm has a market cap of $69,583.77, a price-to-earnings ratio of 13.48, a PEG ratio of 0.66 and a beta of 1.49. The company has a debt-to-equity ratio of 2.29, a current ratio of 4.99 and a quick ratio of 4.80. Celgene Co. has a one year low of $88.32 and a one year high of $147.17.
Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.78 by $0.09. The company had revenue of $3.48 billion during the quarter, compared to analyst estimates of $3.46 billion. Celgene had a net margin of 22.38% and a return on equity of 67.50%. Celgene’s revenue for the quarter was up 16.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.61 EPS. analysts expect that Celgene Co. will post 7.68 earnings per share for the current fiscal year.
In related news, insider Mark J. Alles acquired 3,260 shares of the stock in a transaction dated Thursday, February 8th. The stock was bought at an average price of $91.90 per share, for a total transaction of $299,594.00. Following the purchase, the insider now directly owns 178,904 shares of the company’s stock, valued at approximately $16,441,277.60. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.95% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Hikari Power Ltd Grows Position in Celgene Co. (CELG)” was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.thelincolnianonline.com/2018/02/12/hikari-power-ltd-grows-position-in-celgene-co-celg.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.